Meeting
2013 Gastrointestinal Cancers Symposium
A randomized phase II study of neoadjuvant chemoradiotherapy with 5-FU/leucovorin or irinotecan/S1 in patients with locally advanced rectal cancer.
Authors
Minkyu Jung
Yonsei Cancer Center, Yonsei University College of
Minkyu Jung , Sang Joon Shin , Seungtaek Lim , Ji Soo Park , Woong Sub Koom , Ki Chang Keum , Nam Kyu Kim , Seung Hyuk Back , Byung Soh Min , Hyuk Hur , Ho Geun Kim , Jun Seok Lim , Tae IL Kim , Jae Roh , Young Suk Park , Joong Bae Ahn
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session C: Cancers of the Colon and Rectum
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
NCT01269216
Citation
J Clin Oncol 31, 2013 (suppl 4; abstr511)
DOI
10.1200/jco.2013.31.4_suppl.511
Abstract #
511
Poster Bd #
D11
Abstract Disclosures
Similar Posters
Poster
2021 Gastrointestinal Cancers Symposium
Neoadjuvant chemotherapy with modified FOLFOXIRI for locally advanced rectal cancer: A single center phase II trial.
First Author: Wen Zhang
Poster
2011 ASCO Annual Meeting
Efficacy endpoints of RTOG 0247: A randomized phase II study of neoadjuvant capecitabine (C) and irinotecan (I) or C and oxaliplatin (O) with concurrent radiation therapy (RT) for locally advanced rectal cancer.
First Author: S. J. Wong
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Total neoadjuvant therapy (TnT) with FOLFOX followed by short course radiation in locally advanced rectal cancer: A phase II study.
First Author: Janice Zhao
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Induction FOLFOX prior to CROSS chemoradiotherapy and surgery in patients with locally-advanced esophageal and gastroesophageal junction cancer: A phase II study.
First Author: Richard Francis Dunne